logo
Plus   Neg
Share
Email

Agios Pharma Prices IPO At $18/shr, Above Estimated Range - Quick Facts

Biopharmaceutical company Agios Pharmaceuticals Inc announced the pricing of initial public offering of 5.89 million common shares at $18 per share, before underwriting discounts, which is above its previously estimated range of $14 to $16 per share. The company expects to close the offering on July 29, 2013.

In addition, Agios has granted the underwriters a 30-day option to buy up to 883,333 additional shares at the public offering price, less the underwriting discount.

The Cambridge, Massachusetts-based company's common stock expects to begin trading under the ticker symbol "AGIO" on the NASDAQ Global Select Market on July 24, 2013.

The company, which was founded in 2007, specified that J.P. Morgan and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Cowen and Company and Leerink Swan are acting as co-managers.

Agios reported a net loss of $7.2 million on revenue of $6.3 million for the quarter ended March 31, according to the filing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. auto safety regulator has opened an investigation into about 115,000 Tesla electric vehicles over a front suspension safety issue. The probe covers 2015 through 2017 Model S sedans and 2016 through 2017 Model X SUVs. The investigation comes after Tesla reportedly started a recall over the issue for vehicles in China. Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform
Follow RTT